Protagonist Therapeutics, a Pharmaceutical company based in the United States, has a risk rating score of 27.6, labeling it as a medium-risk investment. Specializing in the development of novel drug candidates through their unique technology platform, Protagonist Therapeutics aims to address medical needs with products like Rusfertide (PTG-300) and JNJ-2113. The company's focus on environment, sustainability, and governance (ESG) sets them apart in the pharmaceutical industry.